#CitiusPharmaceuticals, Inc. $CTXR a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it has initiated the pivotal Phase 3 clinical trial Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). The Phase 3 trial is a multi-center, randomized, double-blind study of 700 subjects.